These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 19635146)

  • 1. Vorinostat in solid and hematologic malignancies.
    Siegel D; Hussein M; Belani C; Robert F; Galanis E; Richon VM; Garcia-Vargas J; Sanz-Rodriguez C; Rizvi S
    J Hematol Oncol; 2009 Jul; 2():31. PubMed ID: 19635146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer.
    Blumenschein GR; Kies MS; Papadimitrakopoulou VA; Lu C; Kumar AJ; Ricker JL; Chiao JH; Chen C; Frankel SR
    Invest New Drugs; 2008 Feb; 26(1):81-7. PubMed ID: 17960324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma.
    Mann BS; Johnson JR; Cohen MH; Justice R; Pazdur R
    Oncologist; 2007 Oct; 12(10):1247-52. PubMed ID: 17962618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma.
    Duvic M; Olsen EA; Breneman D; Pacheco TR; Parker S; Vonderheid EC; Abuav R; Ricker JL; Rizvi S; Chen C; Boileau K; Gunchenko A; Sanz-Rodriguez C; Geskin LJ
    Clin Lymphoma Myeloma; 2009 Dec; 9(6):412-6. PubMed ID: 19951879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma.
    Crump M; Coiffier B; Jacobsen ED; Sun L; Ricker JL; Xie H; Frankel SR; Randolph SS; Cheson BD
    Ann Oncol; 2008 May; 19(5):964-9. PubMed ID: 18296419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vorinostat in cutaneous T-cell lymphoma.
    Duvic M; Vu J
    Drugs Today (Barc); 2007 Sep; 43(9):585-99. PubMed ID: 17940636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL).
    Duvic M; Talpur R; Ni X; Zhang C; Hazarika P; Kelly C; Chiao JH; Reilly JF; Ricker JL; Richon VM; Frankel SR
    Blood; 2007 Jan; 109(1):31-9. PubMed ID: 16960145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes.
    Garcia-Manero G; Yang H; Bueso-Ramos C; Ferrajoli A; Cortes J; Wierda WG; Faderl S; Koller C; Morris G; Rosner G; Loboda A; Fantin VR; Randolph SS; Hardwick JS; Reilly JF; Chen C; Ricker JL; Secrist JP; Richon VM; Frankel SR; Kantarjian HM
    Blood; 2008 Feb; 111(3):1060-6. PubMed ID: 17962510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vorinostat: A novel therapy for the treatment of cutaneous T-cell lymphoma.
    Kavanaugh SM; White LA; Kolesar JM
    Am J Health Syst Pharm; 2010 May; 67(10):793-7. PubMed ID: 20479100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined autophagy and HDAC inhibition: a phase I safety, tolerability, pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the HDAC inhibitor vorinostat in patients with advanced solid tumors.
    Mahalingam D; Mita M; Sarantopoulos J; Wood L; Amaravadi RK; Davis LE; Mita AC; Curiel TJ; Espitia CM; Nawrocki ST; Giles FJ; Carew JS
    Autophagy; 2014 Aug; 10(8):1403-14. PubMed ID: 24991835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer.
    Vansteenkiste J; Van Cutsem E; Dumez H; Chen C; Ricker JL; Randolph SS; Schöffski P
    Invest New Drugs; 2008 Oct; 26(5):483-8. PubMed ID: 18425418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I and pharmacokinetic study of the oral histone deacetylase inhibitor vorinostat in Japanese patients with relapsed or refractory cutaneous T-cell lymphoma.
    Wada H; Tsuboi R; Kato Y; Sugaya M; Tobinai K; Hamada T; Shimamoto T; Noguchi K; Iwatsuki K
    J Dermatol; 2012 Oct; 39(10):823-8. PubMed ID: 22506596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies.
    Ramalingam SS; Parise RA; Ramanathan RK; Lagattuta TF; Musguire LA; Stoller RG; Potter DM; Argiris AE; Zwiebel JA; Egorin MJ; Belani CP
    Clin Cancer Res; 2007 Jun; 13(12):3605-10. PubMed ID: 17510206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study.
    Galanis E; Jaeckle KA; Maurer MJ; Reid JM; Ames MM; Hardwick JS; Reilly JF; Loboda A; Nebozhyn M; Fantin VR; Richon VM; Scheithauer B; Giannini C; Flynn PJ; Moore DF; Zwiebel J; Buckner JC
    J Clin Oncol; 2009 Apr; 27(12):2052-8. PubMed ID: 19307505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies.
    O'Connor OA; Heaney ML; Schwartz L; Richardson S; Willim R; MacGregor-Cortelli B; Curly T; Moskowitz C; Portlock C; Horwitz S; Zelenetz AD; Frankel S; Richon V; Marks P; Kelly WK
    J Clin Oncol; 2006 Jan; 24(1):166-73. PubMed ID: 16330674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of histone deacetylase inhibitors in the treatment of patients with cutaneous T-cell lymphoma.
    Hymes KB
    Clin Lymphoma Myeloma Leuk; 2010 Apr; 10(2):98-109. PubMed ID: 20371442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report.
    Fouladi M; Park JR; Stewart CF; Gilbertson RJ; Schaiquevich P; Sun J; Reid JM; Ames MM; Speights R; Ingle AM; Zwiebel J; Blaney SM; Adamson PC
    J Clin Oncol; 2010 Aug; 28(22):3623-9. PubMed ID: 20606092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study.
    Ramalingam SS; Kummar S; Sarantopoulos J; Shibata S; LoRusso P; Yerk M; Holleran J; Lin Y; Beumer JH; Harvey RD; Ivy SP; Belani CP; Egorin MJ
    J Clin Oncol; 2010 Oct; 28(29):4507-12. PubMed ID: 20837947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Update on the treatment of cutaneous T-cell lymphoma (CTCL): Focus on vorinostat.
    Duvic M; Vu J
    Biologics; 2007 Dec; 1(4):377-92. PubMed ID: 19707308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma.
    Woyach JA; Kloos RT; Ringel MD; Arbogast D; Collamore M; Zwiebel JA; Grever M; Villalona-Calero M; Shah MH
    J Clin Endocrinol Metab; 2009 Jan; 94(1):164-70. PubMed ID: 18854394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.